Comment by European Alzheimer's Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer' s disease

Frank Jessen; Javier Arbizu; Mercé Boada; Mircea Balasa; Karim Bennys; Marina Boban; Katharina Bürger; Andrea Chincarini; Annachiara Cagnin; Peter Paul De Deyn; Emrah Düzel; Sebastiaan Engelborghs; Michael Ewers; Lieza G Exalto; Wiesje M van der Flier; Juan Fortea; Kristian Steen Frederiksen; Giovanni B Frisoni; Lutz Frölich; Alejandro J Garza-Martinez; Timo Grimmer; Bernard Hanseeuw; Jakub Hort; Adrian Ivanoiu; Patrick G Kehoe; Sean P Kennelly; Silke Kern; Stefan Klöppel; Lenka Krajčovičová; Milica G Kramberger; Bernadette McGuinness; Patrizia Mecocci; Timo Jan Oberstein; Pierre-Jean Ousset; Claire Paquet; Robert Perneczky; Fabrizio Piazza; Domenico Plantone; Innocenzo Rainero; Guillaume Sacco; Eric Salmon; Isabel Santana; Nikolaos Scarmeas; Anja Schneider; Jonathan M Schott; Eino Solje; Elka Stefanova; Elisabeth Stögmann; Mélanie Strauss; Stanislav Sutovsky; Gunhild Waldemar; Bengt Winblad

doi:10.1016/j.tjpad.2025.100259

Comment by European Alzheimer's Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer' s disease

Frank Jessen^*
, Javier Arbizu
, Mercé Boada
, Mircea Balasa
, Karim Bennys
, Marina Boban
, Katharina Bürger
, Andrea Chincarini
, Annachiara Cagnin
, Peter Paul De Deyn
, Emrah Düzel
, Sebastiaan Engelborghs
, Michael Ewers
, Lieza G Exalto
, Wiesje M van der Flier
, Juan Fortea
, Kristian Steen Frederiksen
, Giovanni B Frisoni
, Lutz Frölich
, Alejandro J Garza-Martinez

Timo Grimmer, Bernard Hanseeuw, Jakub Hort, Adrian Ivanoiu, Patrick G Kehoe, Sean P Kennelly, Silke Kern, Stefan Klöppel, Lenka Krajčovičová, Milica G Kramberger, Bernadette McGuinness, Patrizia Mecocci, Timo Jan Oberstein, Pierre-Jean Ousset, Claire Paquet, Robert Perneczky, Fabrizio Piazza, Domenico Plantone, Innocenzo Rainero, Guillaume Sacco, Eric Salmon, Isabel Santana, Nikolaos Scarmeas, Anja Schneider, Jonathan M Schott, Eino Solje, Elka Stefanova, Elisabeth Stögmann, Mélanie Strauss, Stanislav Sutovsky, Gunhild Waldemar, Bengt Winblad

^*Corresponding author for this work

Neurologen

Research output: Contribution to journal › Article › Academic › peer-review

2 Downloads (Pure)

Original language	English
Article number	100259
Number of pages	1
Journal	Journal of Prevention of Alzheimer's Disease
Issue number	8
Early online date	9 Jul 2025
DOIs	https://doi.org/10.1016/j.tjpad.2025.100259
Publication status	Published - 27 Aug 2025

Access to Document

10.1016/j.tjpad.2025.100259Licence: CC BY

1-s2.0-S227458072500202X-mainFinal published version, 341 KBLicence: CC BY

Cite this

Jessen, F., Arbizu, J., Boada, M., Balasa, M., Bennys, K., Boban, M., Bürger, K., Chincarini, A., Cagnin, A., De Deyn, P. P., Düzel, E., Engelborghs, S., Ewers, M., Exalto, L. G., van der Flier, W. M., Fortea, J., Frederiksen, K. S., Frisoni, G. B., Frölich, L., ... Winblad, B. (2025). Comment by European Alzheimer's Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer' s disease. Journal of Prevention of Alzheimer's Disease, (8), Article 100259. https://doi.org/10.1016/j.tjpad.2025.100259

@article{a568f8916b4949faae813932435ac3f1,

title = "Comment by European Alzheimer's Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer' s disease",

author = "Frank Jessen and Javier Arbizu and Merc{\'e} Boada and Mircea Balasa and Karim Bennys and Marina Boban and Katharina B{\"u}rger and Andrea Chincarini and Annachiara Cagnin and \{De Deyn\}, \{Peter Paul\} and Emrah D{\"u}zel and Sebastiaan Engelborghs and Michael Ewers and Exalto, \{Lieza G\} and \{van der Flier\}, \{Wiesje M\} and Juan Fortea and Frederiksen, \{Kristian Steen\} and Frisoni, \{Giovanni B\} and Lutz Fr{\"o}lich and Garza-Martinez, \{Alejandro J\} and Timo Grimmer and Bernard Hanseeuw and Jakub Hort and Adrian Ivanoiu and Kehoe, \{Patrick G\} and Kennelly, \{Sean P\} and Silke Kern and Stefan Kl{\"o}ppel and Lenka Kraj{\v c}ovi{\v c}ov{\'a} and Kramberger, \{Milica G\} and Bernadette McGuinness and Patrizia Mecocci and Oberstein, \{Timo Jan\} and Pierre-Jean Ousset and Claire Paquet and Robert Perneczky and Fabrizio Piazza and Domenico Plantone and Innocenzo Rainero and Guillaume Sacco and Eric Salmon and Isabel Santana and Nikolaos Scarmeas and Anja Schneider and Schott, \{Jonathan M\} and Eino Solje and Elka Stefanova and Elisabeth St{\"o}gmann and M{\'e}lanie Strauss and Stanislav Sutovsky and Gunhild Waldemar and Bengt Winblad",

year = "2025",

month = aug,

day = "27",

doi = "10.1016/j.tjpad.2025.100259",

language = "English",

journal = "Journal of Prevention of Alzheimer's Disease",

issn = "2274-5807",

publisher = "Elsevier Masson",

number = "8",

}

Jessen, F, Arbizu, J, Boada, M, Balasa, M, Bennys, K, Boban, M, Bürger, K, Chincarini, A, Cagnin, A, De Deyn, PP, Düzel, E, Engelborghs, S, Ewers, M, Exalto, LG, van der Flier, WM, Fortea, J, Frederiksen, KS, Frisoni, GB, Frölich, L, Garza-Martinez, AJ, Grimmer, T, Hanseeuw, B, Hort, J, Ivanoiu, A, Kehoe, PG, Kennelly, SP, Kern, S, Klöppel, S, Krajčovičová, L, Kramberger, MG, McGuinness, B, Mecocci, P, Oberstein, TJ, Ousset, P-J, Paquet, C, Perneczky, R, Piazza, F, Plantone, D, Rainero, I, Sacco, G, Salmon, E, Santana, I, Scarmeas, N, Schneider, A, Schott, JM, Solje, E, Stefanova, E, Stögmann, E, Strauss, M, Sutovsky, S, Waldemar, G & Winblad, B 2025, 'Comment by European Alzheimer's Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer' s disease', Journal of Prevention of Alzheimer's Disease, no. 8, 100259. https://doi.org/10.1016/j.tjpad.2025.100259

Comment by European Alzheimer's Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer' s disease. / Jessen, Frank; Arbizu, Javier; Boada, Mercé et al.
In: Journal of Prevention of Alzheimer's Disease, No. 8, 100259, 27.08.2025.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Comment by European Alzheimer's Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer' s disease

AU - Jessen, Frank

AU - Arbizu, Javier

AU - Boada, Mercé

AU - Balasa, Mircea

AU - Bennys, Karim

AU - Boban, Marina

AU - Bürger, Katharina

AU - Chincarini, Andrea

AU - Cagnin, Annachiara

AU - De Deyn, Peter Paul

AU - Düzel, Emrah

AU - Engelborghs, Sebastiaan

AU - Ewers, Michael

AU - Exalto, Lieza G

AU - van der Flier, Wiesje M

AU - Fortea, Juan

AU - Frederiksen, Kristian Steen

AU - Frisoni, Giovanni B

AU - Frölich, Lutz

AU - Garza-Martinez, Alejandro J

AU - Grimmer, Timo

AU - Hanseeuw, Bernard

AU - Hort, Jakub

AU - Ivanoiu, Adrian

AU - Kehoe, Patrick G

AU - Kennelly, Sean P

AU - Kern, Silke

AU - Klöppel, Stefan

AU - Krajčovičová, Lenka

AU - Kramberger, Milica G

AU - McGuinness, Bernadette

AU - Mecocci, Patrizia

AU - Oberstein, Timo Jan

AU - Ousset, Pierre-Jean

AU - Paquet, Claire

AU - Perneczky, Robert

AU - Piazza, Fabrizio

AU - Plantone, Domenico

AU - Rainero, Innocenzo

AU - Sacco, Guillaume

AU - Salmon, Eric

AU - Santana, Isabel

AU - Scarmeas, Nikolaos

AU - Schneider, Anja

AU - Schott, Jonathan M

AU - Solje, Eino

AU - Stefanova, Elka

AU - Stögmann, Elisabeth

AU - Strauss, Mélanie

AU - Sutovsky, Stanislav

AU - Waldemar, Gunhild

AU - Winblad, Bengt

PY - 2025/8/27

Y1 - 2025/8/27

U2 - 10.1016/j.tjpad.2025.100259

DO - 10.1016/j.tjpad.2025.100259

M3 - Article

C2 - 40640062

SN - 2274-5807

JO - Journal of Prevention of Alzheimer's Disease

JF - Journal of Prevention of Alzheimer's Disease

IS - 8

M1 - 100259

ER -

Jessen F, Arbizu J, Boada M, Balasa M, Bennys K, Boban M et al. Comment by European Alzheimer's Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer' s disease. Journal of Prevention of Alzheimer's Disease. 2025 Aug 27;(8):100259. Epub 2025 Jul 9. doi: 10.1016/j.tjpad.2025.100259